Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Core Viewpoint - Corvus Pharmaceuticals is actively engaging with investors through one-on-one meetings and a fireside chat at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, scheduled for March 27, 2025 [1]. Group 1 - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various cancer and immune diseases [3]. - The company's lead product candidate is soquelitinib, an investigational oral small molecule drug that selectively inhibits ITK [3]. - Corvus has additional clinical-stage candidates aimed at treating a variety of cancer indications [3]. Group 2 - A live webcast of the fireside chat will be available, along with access for 90 days post-event, through the investor relations section of the Corvus website [2].